InflaRx N.V. Annual Report - How They Did This Year (Fiscal Year Ended December 31, 2025)

Hey there! Thinking about investing in InflaRx N.V. or just curious how they've been doing? You've come to the right place. We'll explain their annual report for the fiscal year ending December 31, 2025. This will help you easily understand the company's situation. You'll see how they performed this past year and what it means for you as an investor. Think of this as a chat with a friend who explains financial stuff without confusing jargon.

We'll cover key information. This includes what they do, their financial health, big successes or challenges, and future plans. We only discuss solid information.

Let's dive in!

Who is InflaRx N.V. and What Do They Do?

InflaRx N.V. is officially based in The Netherlands. Its main offices (headquarters) are in Jena, Germany. They trade on the Nasdaq stock exchange under the ticker symbol IFRX.

Their main goal is to develop new medicines. They focus on complement-mediated immunological and inflammatory diseases. This means they create treatments for conditions where your immune system overreacts. This overreaction causes inflammation and various illnesses. They use special technologies to do this. These technologies target C5a and C5aR. These are key parts of the complement system, involved in inflammatory responses.

They have a couple of key product candidates (medicines they're developing):

• Vilobelimab (also known as GOHIBIC®): This is a first-in-class anti-C5a antibody. They are developing it for acute respiratory distress syndrome (ARDS). ARDS is a severe lung condition. It targets critically ill, mechanically ventilated adult patients. They also explore its use for other serious inflammatory diseases. This includes Pyoderma Gangosum (PG), a rare inflammatory skin disease. It is currently in a Phase 2 clinical trial for PG.
• Izicopan: This is an orally administered C5aR inhibitor. They develop this candidate for chronic inflammatory conditions. These include hidradenitis suppurativa (HS), a chronic inflammatory skin disease. It completed a Phase 2b trial for HS. They also develop it for chronic spontaneous urticaria (CSU), a severe form of hives. A Phase 2 study for CSU is ongoing.

Quick Company Snapshot (as of December 31, 2025)

• Where they're from: The Netherlands (headquarters in Germany)
• Stock Ticker: IFRX (traded on Nasdaq)
• Shares out there: As of December 31, 2025, 72,292,859 ordinary shares existed. This increased from 65,120,000 shares at year-end 2024. A public offering in Q2 2025 caused this increase.
• Accounting Style: They use International Financial Reporting Standards (IFRS). They report numbers in Euros (€). This is a common standard outside the U.S.
• Filing Status: The SEC calls them a "Non-accelerated Filer." This means they are a smaller company. Their public float is under $700 million. They get more time to file reports than larger companies. They are not a "well-known seasoned issuer." This status is for very large, established companies. These companies have a public float of at least $700 million and a history of timely filings.

How They're Looking Ahead (Future Outlook)

InflaRx focuses on the future. They aim to get potential medicines through clinical trials and approved for use. Here's what they highlight:

• Advancing Clinical Trials: They invest heavily in new and ongoing clinical trials. This includes both vilobelimab and izicopan. For vilobelimab, they expect final data from the ARDS Phase 3 trial (NCT04571288) in Q1 2026. Patient enrollment finished in Q3 2025. For izicopan, they plan to start a pivotal Phase 3 program for HS in mid-2026. This builds on positive Phase 2b data. They expect top-line results from the ongoing CSU Phase 2 study in Q4 2026.
• Seeking Approvals: A big goal is getting regulatory approval for their product candidates. For example, they prepare a Biologics License Application (BLA) for GOHIBIC (vilobelimab). This BLA is for ARDS treatment in the U.S. They aim to submit it to the FDA in Q2 2026. They also plan to submit a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA). This MAA is for vilobelimab for ARDS in late 2026.
• Potential Partnerships: They seek partners for programs like izicopan or vilobelimab (for PG). A strategic partnership for izicopan could involve an upfront payment of €50-100 million. This is especially for global commercialization. It could also include milestone payments and royalties. This would help offset development costs and expand market reach.
• Leveraging Technology: They plan to keep using their core anti-C5a and anti-C5aR technologies. This helps them find more treatments for immune-related diseases. Early-stage research explores new targets within the complement pathway.

Potential Roadblocks & What to Watch Out For (Risk Factors)

Investing in InflaRx carries risks. This is especially true for a company developing new medicines. The company highlights several things that could affect its future. Here are some key risks to consider:

• Clinical Trial Uncertainty: Developing new drugs is tough! Success for vilobelimab and izicopan trials is not guaranteed. Results might not meet expectations. Trials could take longer or cost more. For example, the vilobelimab ARDS Phase 3 trial might fail. Unexpected safety concerns could also arise. This could cause delays or require more costly trials. The program might even be abandoned. This would severely impact the company's value and future.
• Regulatory Hurdles: Even with successful trials, approval is challenging. Health authorities like the FDA (U.S.) or EMA (Europe) must approve drugs. There is no guarantee they will accept results or approve drugs. An FDA complete response letter (CRL) could delay approval. This delay could last a year or more. It might require more clinical data or manufacturing changes. This pushes back potential income and increases costs.
• Need for More Money: Developing medicines is very expensive. The company will likely need more money. They might need €100-150 million in 12-18 months. This funds ongoing trials and pre-commercial activities. They might sell more shares. This could mean more shares issued, reducing your ownership percentage.
• Competition: They face competition. Other companies develop similar treatments. For ARDS, competitors develop other anti-inflammatory agents or supportive care therapies. For HS and CSU, approved treatments already exist. Other pipeline candidates also exist. Examples include AbbVie (Humira), Novartis (Xolair), or UCB (Bimzelx). These could limit InflaRx's market share and pricing power, even if their drugs are approved.
• International Operations and Legal Stuff: InflaRx is based in the Netherlands. Its headquarters are in Germany. Many key people are outside the U.S. U.S. investors might find it hard to enforce U.S. legal judgments. This applies to the company or its executives. If a U.S. investor wins a lawsuit in a U.S. court, they might face challenges collecting that judgment. Collecting in European countries could be costly.

The annual report has a dedicated "Risk Factors" section (Item 3.D) that goes into much more detail about these and other potential challenges. It's always a good idea to read that section carefully!

Financial Health & Business Performance

For the fiscal year ending December 31, 2025, InflaRx N.V. remained a clinical-stage biopharmaceutical company. They focused mainly on research and development.

• Revenue: The company reported €18.5 million in total revenue for 2025. This is a big increase from €10.2 million in 2024. Collaboration agreements and government grants generated this income. These related to their development programs. Milestone payments from a regional grant for vilobelimab's ARDS program contributed most.
• Research & Development (R&D) Expenses: R&D expenses were their largest operating cost. They totaled €88.3 million in 2025, up from €75.5 million in 2024. Increased clinical trial activities caused this rise. This includes vilobelimab (ARDS Phase 3) and izicopan (HS Phase 2b completion and CSU Phase 2 initiation). Higher personnel costs from expanding their scientific team also contributed.
• General & Administrative (G&A) Expenses: G&A expenses were €28.1 million in 2025. This compares to €25.0 million in 2024. Higher legal and consulting fees caused this small increase. These fees related to vilobelimab's regulatory preparations. Costs of being a publicly traded company also rose.
• Net Loss: InflaRx reported a €97.9 million loss for 2025. This loss grew from €89.0 million in 2024. Heavy R&D investments and limited income caused this. This loss means €1.36 per share in 2025. It was €1.37 per share in 2024. The increased number of shares outstanding explains the difference.
• Cash and Cash Equivalents: As of December 31, 2025, the company had €135.2 million in cash. This is down from €180.5 million at year-end 2024. This cash includes about €60 million from a Q2 2025 public offering. Management expects current cash to fund operations into Q3 2027. Their cash burn rate is €20-25 million per quarter. They will need more money. This will complete vilobelimab's commercialization and advance izicopan through pivotal trials.